Literature DB >> 22124368

Radiotherapy: the importance of local control in pancreatic cancer.

Edgar Ben-Josef, Theodore S Lawrence.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22124368     DOI： 10.1038/nrclinonc.2011.182

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  9 in total

1.  Full-dose gemcitabine and concurrent radiotherapy for unresectable pancreatic cancer.

Authors:  James D Murphy; Saroja Adusumilli; Kent A Griffith; Michael E Ray; Mark M Zalupski; Theodore S Lawrence; Edgar Ben-Josef
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-03-26       Impact factor: 7.038

2.  Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial.

Authors:  Patrick J Loehrer; Yang Feng; Higinia Cardenes; Lynne Wagner; Joanna M Brell; David Cella; Patrick Flynn; Ramesh K Ramanathan; Christopher H Crane; Steven R Alberts; Al B Benson
Journal:  J Clin Oncol       Date:  2011-10-03       Impact factor: 44.544

3.  Feasibility and efficacy of high dose conformal radiotherapy for patients with locally advanced pancreatic carcinoma.

Authors:  H M Ceha; G van Tienhoven; D J Gouma; C H Veenhof; C J Schneider; E A Rauws; S S Phoa; D González González
Journal:  Cancer       Date:  2000-12-01       Impact factor: 6.860

4.  Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer.

Authors:  C J McGinn; M M Zalupski; I Shureiqi; J M Robertson; F E Eckhauser; D C Smith; D Brown; G Hejna; M Strawderman; D Normolle; T S Lawrence
Journal:  J Clin Oncol       Date:  2001-11-15       Impact factor: 44.544

Review 5.  Antimetabolite radiosensitizers.

Authors:  Donna S Shewach; Theodore S Lawrence
Journal:  J Clin Oncol       Date:  2007-09-10       Impact factor: 44.544

Review 6.  Role of intensity-modulated radiation therapy in gastrointestinal cancer.

Authors:  Marcia Bockbrader; Edward Kim
Journal:  Expert Rev Anticancer Ther       Date:  2009-05       Impact factor: 4.512

7.  DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer.

Authors:  Christine A Iacobuzio-Donahue; Baojin Fu; Shinichi Yachida; Mingde Luo; Hisashi Abe; Clark M Henderson; Felip Vilardell; Zheng Wang; Jesse W Keller; Priya Banerjee; Joseph M Herman; John L Cameron; Charles J Yeo; Marc K Halushka; James R Eshleman; Marian Raben; Alison P Klein; Ralph H Hruban; Manuel Hidalgo; Daniel Laheru
Journal:  J Clin Oncol       Date:  2009-03-09       Impact factor: 44.544

8.  Radiosensitization of pancreatic cancer cells by 2',2'-difluoro-2'-deoxycytidine.

Authors:  T S Lawrence; E Y Chang; T M Hahn; L W Hertel; D S Shewach
Journal:  Int J Radiat Oncol Biol Phys       Date:  1996-03-01       Impact factor: 7.038

9.  Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study.

Authors:  B Chauffert; F Mornex; F Bonnetain; P Rougier; C Mariette; O Bouché; J F Bosset; T Aparicio; L Mineur; A Azzedine; P Hammel; J Butel; N Stremsdoerfer; P Maingon; L Bedenne
Journal:  Ann Oncol       Date:  2008-05-07       Impact factor: 32.976
  9 in total
  13 in total

1.  Sensitization of pancreatic cancer to chemoradiation by the Chk1 inhibitor MK8776.

Authors:  Carl G Engelke; Leslie A Parsels; Yushen Qian; Qiang Zhang; David Karnak; Jordan R Robertson; Daria M Tanska; Dongping Wei; Mary A Davis; Joshua D Parsels; Lili Zhao; Joel K Greenson; Theodore S Lawrence; Jonathan Maybaum; Meredith A Morgan
Journal:  Clin Cancer Res       Date:  2013-06-26       Impact factor: 12.531

2.  Identification of distinct phenotypes of locally advanced pancreatic adenocarcinoma.

Authors:  Minyuen Teo; Grace F Crotty; Criostóir O'Súilleabháin; Paul F Ridgway; Kevin C Conlon; Derek G Power; Ray S McDermott
Journal:  J Gastrointest Cancer       Date:  2013-03

Review 3.  Is concomitant radiotherapy necessary with gemcitabine-based chemotherapy in pancreatic cancer?

Authors:  Xin Zhang; He-Jing Huang; Dan Feng; De-Jun Yang; Chang-Ming Wang; Qing-Ping Cai
Journal:  World J Gastroenterol       Date:  2014-12-14       Impact factor: 5.742

4.  Comparison of four target volume definitions for pancreatic cancer. Guidelines for treatment of the lymphatics and the primary tumor.

Authors:  E Fokas; C Eccles; N Patel; K-Y Chu; S Warren; W Gillies McKenna; T B Brunner
Journal:  Strahlenther Onkol       Date:  2013-04-05       Impact factor: 3.621

5.  Combination of carbon ion beam and gemcitabine causes irreparable DNA damage and death of radioresistant pancreatic cancer stem-like cells in vitro and in vivo.

Authors:  Sei Sai; Toshifumi Wakai; Guillaume Vares; Shigeru Yamada; Takehiko Kamijo; Tadashi Kamada; Toshiyuki Shirai
Journal:  Oncotarget       Date:  2015-03-20

6.  Comparison of investigator-delineated gross tumour volumes and quality assurance in pancreatic cancer: Analysis of the on-trial cases for the SCALOP trial.

Authors:  Emmanouil Fokas; Emiliano Spezi; Neel Patel; Chris Hurt; Lisette Nixon; Kwun-Ye Chu; John Staffurth; Ross Abrams; Somnath Mukherjee
Journal:  Radiother Oncol       Date:  2016-08-03       Impact factor: 6.280

7.  microRNA-193a stimulates pancreatic cancer cell repopulation and metastasis through modulating TGF-β2/TGF-βRIII signalings.

Authors:  Chi Fang; Chen-Yun Dai; Zhu Mei; Ming-Jie Jiang; Dian-Na Gu; Qian Huang; Ling Tian
Journal:  J Exp Clin Cancer Res       Date:  2018-02-13

8.  Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation.

Authors:  E Fokas; R Prevo; J R Pollard; P M Reaper; P A Charlton; B Cornelissen; K A Vallis; E M Hammond; M M Olcina; W Gillies McKenna; R J Muschel; T B Brunner
Journal:  Cell Death Dis       Date:  2012-12-06       Impact factor: 8.469

9.  ARCII: A phase II trial of the HIV protease inhibitor Nelfinavir in combination with chemoradiation for locally advanced inoperable pancreatic cancer.

Authors:  James M Wilson; Emmanouil Fokas; Susan J Dutton; Neel Patel; Maria A Hawkins; Cynthia Eccles; Kwun-Ye Chu; Lisa Durrant; Aswin G Abraham; Mike Partridge; Martha Woodward; Eric O'Neill; Tim Maughan; W Gillies McKenna; Somnath Mukherjee; Thomas B Brunner
Journal:  Radiother Oncol       Date:  2016-04-23       Impact factor: 6.280

10.  An efficient and robust MRI-guided radiotherapy planning approach for targeting abdominal organs and tumours in the mouse.

Authors:  Veerle Kersemans; John S Beech; Stuart Gilchrist; Paul Kinchesh; Philip D Allen; James Thompson; Ana L Gomes; Zenobia D'Costa; Luke Bird; Iain D C Tullis; Robert G Newman; Aurelien Corroyer-Dulmont; Nadia Falzone; Abul Azad; Katherine A Vallis; Owen J Sansom; Ruth J Muschel; Borivoj Vojnovic; Mark A Hill; Emmanouil Fokas; Sean C Smart
Journal:  PLoS One       Date:  2017-04-28       Impact factor: 3.752
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.